Berhe, Oksana
Moessnang, Carolin
Reichert, Markus
Ma, Ren
Höflich, Anna
Tesarz, Jonas
Heim, Christine M.
Ebner-Priemer, Ulrich
Meyer-Lindenberg, Andreas
Tost, Heike
Funding for this research was provided by:
Zentralinstitut für Seelische Gesundheit (ZI)
Article History
Received: 27 October 2022
Accepted: 28 March 2023
First Online: 20 April 2023
Declarations
:
: The study approved by the Medical Ethics Committee II of the Medical Faculty Mannheim at the Ruprecht-Karls-University in Heidelberg, Germany. All participants provided written informed consent for the participation in the study.
: Not applicable.
: Dr Meyer-Lindenberg has received lecture fees from the Lundbeck International Foundation, Paul-Martini-Stiftung, Lilly Deutschland, Atheneum, Fama Public Relations, IDIBAPS, Janssen-Cilag, Hertie-Stiftung, Bodelschwingh-Klinik, Pfizer, Universität Freiburg, Schizophrenia Academy, Hong Kong Society of Biological Psychiatry, Spanish Society of Psychiatry, Italian Society of Biological Psychiatry, Reunions I Ciencia S.L. Brain Center Rudolf Magnus UMC Utrecht, Friedrich-Merz-Stiftung, and consultant fees from Boehringer Ingelheim, Elsevier, Brainsway, Lundbeck Int. Neuroscience Foundation, Lundbeck A/S, Sumitomo Dainippon Pharma Co., Academic Medical Center of the University of Amsterdam, Synapsis Foundation-Alzheimer Research Switzerland, IBS Center for Synaptic Brain Dysfunction, Blueprint Partnership, University of Cambridge, Dt. Zentrum für Neurodegenerative Erkrankungen, Zürich University, Brain Mind Institute, L.E.K. Consulting, ICARE Schizophrenia, Science Advances, Fondation FondaMental, von Behring Röntgen Stiftung, The Wolfson Foundation, Sage Therapeutics. Dr. Ebner-Priemer reports consultancy for Boehringer-Ingelheim. The other authors report no biomedical financial interests or potential conflicts of interest.